Truist initiated coverage of Septerna (SEPN) with a Buy rating and $34 price target The firm says the company’s SEP-631 is in Phase 1 for chronic ...

Septerna just entered the clinic, and its lack of human data makes it an outlier among the companies able to successfully go public this year in what is still a cautious biotech IPO market. What the ...

On Monday, HC Wainwright initiated coverage on Septerna, Inc. (NASDAQ:SEPN), citing a next-generation drug design platform aimed at hitherto-undruggable targets. Septerna is working on G ...

We recently compiled a list of the 10 Best Rebound Stocks To Invest In Now. In this article, we are going to take a look at ...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...

Analysts' ratings for Septerna (NASDAQ:SEPN) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a snapshot of their recent ratings, showcasing how ...

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company’s innovative GPCR ...

(Reuters) -Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of $970 million. The company's shares opened at $23.5 in their ...

For scientists developing new drugs, it’s hard to go wrong targeting a family of receptors that regulate virtually every known process in human beings. G protein-coupled receptors (GPCRs) are found ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, presented new preclinical data from its parathyroid ...

Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for ...

Septerna, Inc. (SEPN) shares soared 7% in the last trading session to close at $22.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...